Amredobresib（Cat No.:I045122）is an investigational small-molecule inhibitor targeting bromodomain and extraterminal domain (BET) proteins, which regulate gene expression by interacting with acetylated histones. By inhibiting BET proteins such as BRD2, BRD3, and BRD4, Amredobresib disrupts the transcription of oncogenes like MYC, leading to reduced tumor cell proliferation and survival. It is being developed for the treatment of solid tumors and hematologic malignancies, including prostate cancer and lymphoma. Amredobresib may also enhance the efficacy of immunotherapy and combination regimens. Supplied for research into epigenetic modulation and transcription-driven cancer therapies.